

S 3466

Accelerating New Pharmaceutical Competition Act

Congress: 114 (2015–2017, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Sep 29, 2016

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sep 29, 2016)

Official Text: <https://www.congress.gov/bill/114th-congress/senate-bill/3466>

Sponsor

Name: Sen. Paul, Rand [R-KY]

Party: Republican • **State:** KY • **Chamber:** Senate

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

| Committee | Chamber | Activity | Date |
|--------------------------------------------------|---------|-------------|--------------|
| Health, Education, Labor, and Pensions Committee | Senate | Referred To | Sep 29, 2016 |

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Sep 29, 2016)

Accelerating New Pharmaceutical Competition Act

This bill amends the Federal Food, Drug, and Cosmetic Act to permit brand name drug applications to rely upon investigations conducted in certain foreign countries if the drug has been approved in the foreign country where the investigations were conducted. The Food and Drug Administration (FDA) has 90 days to act on these applications.

The bill revises a provision regarding the effective date of the approval of a generic drug that is subject to a patent infringement action.

The FDA must prioritize the review of, and act within 150 days on, generic drug applications or supplements to generic drug applications for drugs: (1) for which there is a shortage, or (2) that have not been recently introduced to the market by more than one manufacturer and for which tentative approval has not been granted to more than two applications.

Actions Timeline

- **Sep 29, 2016:** Introduced in Senate
- **Sep 29, 2016:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.